Sagent Pharmaceuticals has introduced Acetazolamide for Injection, USP specified for adjunctive treatment of edema due to congestive heart failure, drug-induced edema, centrencephalic epilepsies and chronic simple glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma.
The product offered in a latex-free vial is generic equivalent to the carbonic anhydrase inhibitor Diamox.
Acetazolamide for Injection features Sagent's PreventIV Measures packaging and labeling, which intends to minimize medication errors and provide information related to indications, side effect profile and prescribing information.
IMS data reported $9.5m US market of Acetazolamide for Injection, USP for the 12 months ending September 2012.
